Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AMMECR nuclear protein 1 is a highly conserved nuclear protein encoded by the *AMMECR1* gene on Xq22.3. This protein is defined by a RAGNYA fold, suggesting potential interaction with nucleic acids or nucleotides, and is thought to participate in fundamental cellular processes within the nucleus. Mutations, deletions, or loss-of-function variants of AMMECR1 are implicated in a contiguous gene deletion syndrome characterized by Alport syndrome, intellectual disability, midface hypoplasia, elliptocytosis, cardiac and skeletal malformations, and hearing loss. AMMECR1 may play a role in regulating cell cycle progression and growth; for example, downregulation in lung cancer cell lines suppresses proliferation and induces apoptosis. Despite conservation and disease association, its precise molecular function is unknown and it is not considered a therapeutic drug target at this time[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AMMECR nuclear protein 1 (AMMECR1).